As of Friday, November 07, Molecular Partners AG’s MOLN share price has dipped by 15.17%, which has investors questioning if ...
Allogene Therapeutics, Inc. downgraded to Hold after ALPHA3 trial setbacks. Review updated pipeline prospects and risks.
Q3 2025 Management View CEO David Chang emphasized conviction in the company’s allogeneic platform, stating the focus is on “delivering what patients need now” and making “the promise of curative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback